The Chrysalin® Solution for Cardiovascular Disease
Cardiovascular disease is the single largest killer of Americans, claiming the lives of almost one million people annually (American Heart Association). Approximately 55% of these deaths are related to coronary heart disease, which includes acute myocardial infarction (heart attack), angina, atherosclerotic cardiovascular disease, and all other forms of chronic ischemic heart disease. According to the American Heart Association, approximately 16 million Americans have coronary heart disease with estimated annual direct treatment costs of over $100 billion. Thus, development of a drug that can reverse effects of cardiovascular disease may literally save millions of lives, improve life quality of those with cardiovascular disease, and reduce the cost of cardiovascular health care.
Preclinical studies have shown that TP508 treatment:
- Reduces formation of atherosclerotic vascular occlusions following balloon angioplasty in high cholesterol rabbits by more than 50%
- Restores blood flow and function to ischemic heart muscle in pigs with experimentally-induced chronic myocardial ischemia
- Reverses endothelial dysfunction in ischemic blood vessels and coronary artery endothelial cells making the vessels and cells more responsive to natural stimulation and participation in tissue revascularization and repair
- Reduces myocardial infarct damage to heart muscle in both health animals, as well as those with high cholesterol and diabetes in models that mimic effects of human heart attacks in patients with preexisting cardiovascular disease
The capacity of TP508 to unlock protective and regenerative processes that counteract cardiovascular disease under these different pathological conditions is based on its unique mode of action involving restoration of endothelial function and activation of endothelial progenitor cells.